About

Who We Are

Piccolo Biosystems is a biotechnology company advancing precision medicine and drug discovery through single-cell functional biochemistry.

We develop technologies that measure how drugs actually behave inside patient-derived cells, providing functional insight that complements genomics, proteomics, and imaging.

Our Mission

To enable better therapies by revealing functional drug response at the single-cell level.

We believe precision medicine requires direct measurement of biological activity—especially in heterogeneous cell populations where resistance and treatment failure originate.

What We Do

Piccolo’s core platform, PiccoPath™, measures enzyme activity in ultrasmall samples, down to single cells, generating functional data that is inaccessible with conventional approaches.

Our technology enables:

Direct target engagement measurement
Early drug resistance detection
Mechanistic insight into combination therapies
AI-ready functional datasets grounded in real biochemistry

We deploy first as Research Use Only (RUO) in pharma and biotech programs, with a clear path toward clinical diagnostics.

Why It Matters

Many drug programs fail because functional response is inferred rather than measured, and cellular heterogeneity is overlooked. Piccolo provides cell-by-cell functional data to help teams make earlier, higher-confidence decisions in discovery and translational development.

Our Focus

Our platform is broadly applicable, with initial focus in areas where cellular heterogeneity drives outcomes:

Oncology
Autoimmune and inflammatory disease
Neurodegenerative disorders

Our Approach

Piccolo combines:

Microengineered biochemical assays
Single-cell resolution
Scalable, cost-efficient workflows
Data designed for AI and advanced analytics

Together, these elements enable a new standard for functional precision medicine.